Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06534411
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
A Research Study to See How Much CagriSema 10 mg Once Weekly Lowers Blood Sugar and Body Weight Compared to Tirzepatide 5 mg Once Weekly in People With Type 2 Diabetes Treated With Metformin SGLT2 Inhibitor or Both
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide CagriSema 10 mg10 mg sc Once Weekly Versus Tirzepatide 5 mg sc Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin SGLT2 Inhibitor or Both
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REIMAGINE 5
Brief Summary:
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes CagriSema is a new investigational medicine Doctors cannot yet prescribe CagriSema CagriSema will be compared to a medicine called tirzepatide Doctors can prescribe tirzepatide in some countries Participants will either receive CagriSema or tirzepatide Which treatment the participant will receive is decided by chance For each participant the study will last for up to 1 year and 4 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None